AXSM: Axsome Therapeutics Inc. Stocks News on July 1, 2025

AXSM

MT Newswires

7 days ago

Axsome Therapeutics Insider Sold Shares Worth $1,370,647, According to a Recent SEC Filing

Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month

AXSM

GlobeNewswire

11 days ago

Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month

AXSM

Simply Wall St.

13 days ago

Axsome Therapeutics, Inc. (NASDAQ:AXSM): When Will It Breakeven?

Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS)

AXSM

GlobeNewswire

13 days ago

Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS)

Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders

AXSM

GlobeNewswire

15 days ago

Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders

Axsome’s AXS-14 Gets Regulatory Setback with RTF, says Morgan Stanley

AXSM

Insider Monkey

20 days ago

Axsome’s AXS-14 Gets Regulatory Setback with RTF, says Morgan Stanley

Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025

AXSM

GlobeNewswire

20 days ago

Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025

Axsome Therapeutics Announces Availability of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults

AXSM

GlobeNewswire

21 days ago

Axsome Therapeutics Announces Availability of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults

Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia

AXSM

GlobeNewswire

22 days ago

Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia

2 Soaring Stocks Wth More Upside Potential

AXSM

Motley Fool

a month ago

2 Soaring Stocks Wth More Upside Potential

Will Tesla have to play catch up to Waymo's robotaxis?

AXSM

Yahoo Finance Video

a month ago

Will Tesla have to play catch up to Waymo's robotaxis?

Why Scott Bessent wants to make it easier for banks to own Treasurys

AXSM

Yahoo Finance

a month ago

Why Scott Bessent wants to make it easier for banks to own Treasurys

EKOUAER Launches Wedding Season Special Edition and Joins The Knot Registry

AXSM

GlobeNewswire

a month ago

EKOUAER Launches Wedding Season Special Edition and Joins The Knot Registry

AXSM

GlobeNewswire

a month ago

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Statement by Minister Guilbeault on Portuguese Heritage Month

AXSM

CNW Group

a month ago

Statement by Minister Guilbeault on Portuguese Heritage Month

‘All the crypto cowboys are gone’: Kevin O’Leary says the sector is safe now and is backing stablecoins

AXSM

Moneywise

a month ago

‘All the crypto cowboys are gone’: Kevin O’Leary says the sector is safe now and is backing stablecoins

Be Sure To Check Out TEGNA Inc. (NYSE:TGNA) Before It Goes Ex-Dividend

AXSM

Simply Wall St.

a month ago

Be Sure To Check Out TEGNA Inc. (NYSE:TGNA) Before It Goes Ex-Dividend

If EPS Growth Is Important To You, DocuSign (NASDAQ:DOCU) Presents An Opportunity

AXSM

Simply Wall St.

a month ago

If EPS Growth Is Important To You, DocuSign (NASDAQ:DOCU) Presents An Opportunity

Axsome Therapeutics to Participate in Upcoming Investor Conferences

AXSM

GlobeNewswire

a month ago

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

AXSM

GlobeNewswire

a month ago

Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.

AXSM

GlobeNewswire

a month ago

Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.

3 High-Flying Stocks That Could Soar Even More

AXSM

Motley Fool

a month ago

3 High-Flying Stocks That Could Soar Even More

Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone

AXSM

GlobeNewswire

2 months ago

Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone

Prediction: These 2 Stocks Will Outperform the Market in the Next Five Years

AXSM

Motley Fool

2 months ago

Prediction: These 2 Stocks Will Outperform the Market in the Next Five Years

AXSM

Motley Fool

2 months ago

3 Monster Stocks in the Making

AXSM

Simply Wall St.

2 months ago

Analysts Are Updating Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Estimates After Its First-Quarter Results

AXSM

GuruFocus.com

2 months ago

Axsome Therapeutics Inc (AXSM) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and ...

AXSM

Thomson Reuters StreetEvents

2 months ago

Q1 2025 Axsome Therapeutics Inc Earnings Call

AXSM

Simply Wall St.

2 months ago

The three-year returns have been enviable for Axsome Therapeutics (NASDAQ:AXSM) shareholders despite underlying losses increasing

Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

AXSM

GlobeNewswire

2 months ago

Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

AXSM

GlobeNewswire

2 months ago

Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

AXSM

Zacks

2 months ago

Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline

AXSM

GlobeNewswire

2 months ago

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Seeking Recession-Proof Stocks? RBC Suggests 2 Healthcare Stocks to Buy

AXSM

TipRanks

3 months ago

Seeking Recession-Proof Stocks? RBC Suggests 2 Healthcare Stocks to Buy

Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5

AXSM

GlobeNewswire

3 months ago

Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5

Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting

AXSM

GlobeNewswire

3 months ago

Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting

Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week

AXSM

Investor's Business Daily

3 months ago

Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week

Why Shares of Axsome Therapeutics Slumped Today

AXSM

Motley Fool

3 months ago

Why Shares of Axsome Therapeutics Slumped Today

Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)

AXSM

GlobeNewswire

3 months ago

Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)

IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried.

AXSM

Investor's Business Daily

3 months ago

IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried.

Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint

AXSM

GlobeNewswire

3 months ago

Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint

AXSM

Zacks

3 months ago

Axsome (AXSM) Down 0.8% Since Last Earnings Report: Can It Rebound?

AXSM

Insider Monkey

4 months ago

Is Axsome Therapeutics, Inc. (AXSM) the Best Performing Growth Stock in 2025?

AXSM

Zacks

4 months ago

AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals

Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA

AXSM

GlobeNewswire

4 months ago

Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission

AXSM

GlobeNewswire

4 months ago

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission

AXSM

Insider Monkey

4 months ago

Why Axsome Therapeutics, Inc. (AXSM) is Skyrocketing So Far in 2025

AXSM

GlobeNewswire

4 months ago

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Axsome Therapeutics Full Year 2024 Earnings: EPS Misses Expectations

AXSM

Simply Wall St.

4 months ago

Axsome Therapeutics Full Year 2024 Earnings: EPS Misses Expectations

Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs

AXSM

Benzinga

4 months ago

Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs

Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors

AXSM

GlobeNewswire

4 months ago

Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors

AXSM

Insider Monkey

4 months ago

Why Axsome Therapeutics, Inc. (AXSM) is the Best Performing Pharma Stock So Far in 2025

These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50

AXSM

Investor's Business Daily

4 months ago

These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50

AXSM

Insider Monkey

4 months ago

Axsome Therapeutics, Inc. (AXSM): the Best Performing Healthcare Stock So Far in 2025

AXSM

GuruFocus.com

4 months ago

Axsome Therapeutics Inc (AXSM) Q4 2024 Earnings Call Highlights: Robust Revenue Growth Amid ...

AXSM

Thomson Reuters StreetEvents

4 months ago

Q4 2024 Axsome Therapeutics Inc Earnings Call

AXSM

Motley Fool

4 months ago

Axsome Therapeutics (AXSM) Q4 2024 Earnings Call Transcript

Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

AXSM

GlobeNewswire

4 months ago

Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy?

AXSM

Motley Fool

5 months ago

This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy?

AXSM

Insider Monkey

5 months ago

Why Axsome Therapeutics (AXSM) Is Advancing Today

Why Axsome Therapeutics Stock Is Soaring Today

AXSM

Motley Fool

5 months ago

Why Axsome Therapeutics Stock Is Soaring Today

Axsome Stock Surges 20% on Auvelity Patent Settlement With Teva

AXSM

Zacks

5 months ago

Axsome Stock Surges 20% on Auvelity Patent Settlement With Teva

AXSM

Zacks

5 months ago

Axsome (AXSM) Surges 20.2%: Is This an Indication of Further Gains?

Why Axsome Therapeutics Stock Is Skyrocketing Today

AXSM

Motley Fool

5 months ago

Why Axsome Therapeutics Stock Is Skyrocketing Today

Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'

AXSM

Benzinga

5 months ago

Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'

Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation

AXSM

GlobeNewswire

5 months ago

Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation

Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises

AXSM

Zacks

5 months ago

Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises

Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader

AXSM

GlobeNewswire

5 months ago

Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader

Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults

AXSM

GlobeNewswire

5 months ago

Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults

Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18

AXSM

GlobeNewswire

5 months ago

Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18

BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.

AXSM

Investor's Business Daily

6 months ago

BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue

AXSM

GlobeNewswire

6 months ago

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue

AXSM

Simply Wall St.

6 months ago

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Profit Outlook

Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results

AXSM

Benzinga

6 months ago

Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results

Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation

AXSM

Investor's Business Daily

6 months ago

Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation

AXSM

GlobeNewswire

6 months ago

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation

AXSM

Zacks

7 months ago

Why Is Axsome (AXSM) Down 0.1% Since Last Earnings Report?

Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says

AXSM

Benzinga

7 months ago

Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says

AXSM

Simply Wall St.

7 months ago

Axsome Therapeutics' (NASDAQ:AXSM) growing losses don't faze investors as the stock ascends 5.5% this past week

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy

AXSM

GlobeNewswire

7 months ago

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy

Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up

AXSM

Zacks

8 months ago

Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up

AXSM

Thomson Reuters StreetEvents

8 months ago

Q3 2024 Axsome Therapeutics Inc Earnings Call

AXSM

Motley Fool

8 months ago

Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript

AXSM

GuruFocus.com

8 months ago

Axsome Hits 52-Week High After Surging Nearly 5%--FDA Milestones Could Fuel Even Bigger Gains

Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

AXSM

GlobeNewswire

8 months ago

Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024

AXSM

GlobeNewswire

8 months ago

Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024

AXSM

Zacks

8 months ago

Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for

Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024

AXSM

GlobeNewswire

8 months ago

Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024

3 Bargain Stocks to Buy in a Market That's Priced for Perfection

AXSM

Motley Fool

8 months ago

3 Bargain Stocks to Buy in a Market That's Priced for Perfection

Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12

AXSM

GlobeNewswire

9 months ago

Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12

1 Under-the-Radar Biotech Stock to Buy and Hold

AXSM

Motley Fool

9 months ago

1 Under-the-Radar Biotech Stock to Buy and Hold

Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024

AXSM

GlobeNewswire

9 months ago

Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024

AXSM

Zacks

10 months ago

FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

AXSM

GlobeNewswire

10 months ago

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

Axsome Therapeutics to Participate in Investor Conferences in September

AXSM

GlobeNewswire

10 months ago

Axsome Therapeutics to Participate in Investor Conferences in September

Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.

AXSM

GlobeNewswire

10 months ago

Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.

AXSM

Insider Monkey

a year ago

Jim Cramer Thinks Axsome Therapeutics Inc (NASDAQ:AXSM) Stock Can Double

AXSM

Motley Fool

a year ago

Axsome Therapeutics (AXSM) Q2 2024 Earnings Call Transcript

Why Axsome Therapeutics Stock Is Sinking Today

AXSM

Motley Fool

a year ago

Why Axsome Therapeutics Stock Is Sinking Today

AXSM

Zacks

a year ago

Latest Axsome Therapeutics Inc. (AXSM) News on July 1, 2025

Share on Social Networks: